FDA Inspection
GlaxoSmithKline Biologicals SAGlaxoSmithKline Biologicals SA – FDA Inspection, Feb 27, 2026
Record Details
This FDA Inspection record concerns GlaxoSmithKline Biologicals SA, with an inspection on February 27, 2026, issued by the Office of Inspections and Investigations, covering biologics.
View Company Profile
ID · a737c389-4e6a-4fcc-94cb-27544c5ade52
Inspection Facts
- Inspection number
- 1304664
- FDA center
- Biologics
Other FDA inspections of GlaxoSmithKline Biologicals SA
6| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2023 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| June 24, 2019 | Not classified | Office of Inspections and Investigations | |
| January 27, 2017 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| October 2, 2014 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| October 5, 2012 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
Other documents for GlaxoSmithKline Biologicals SA
- FDA Inspection 1215345 - 2023-06-23
- FDA Inspection 1099397 - 2019-06-24
- FDA Inspection 1007184 - 2017-01-27
- FDA Inspection 900625 - 2014-10-02
- FDA Inspection 818683 - 2012-10-05
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.